Acute Post Surgical Hypoparathyroidism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute post surgical hypoparathyroidism. 27 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
27
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Post Surgical Hypoparathyroidism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ascendis Pharma Bone 27 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute post surgical hypoparathyroidism. Each bar = one year. Y-axis scaled to peak year (21 patents).

3
31
21
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Yorvipath
PALOPEGTERIPARATIDE
 Ascendis Pharma Bone 27 61 — 2031-04-30

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8906847 Yorvipath method of use 81 2031-04-30
8906847 Yorvipath method of use 81 2031-04-30
8906847 Yorvipath method of use 81 2031-04-30
11857603 Yorvipath method of use 75 2037-09-28
11590207 Yorvipath method of use 75 2037-09-28
12453778 Yorvipath method of use 75 2037-09-28
12453778 Yorvipath method of use 75 2037-09-28
12295989 Yorvipath method of use 75 2037-09-28
12295989 Yorvipath method of use 75 2037-09-28
12453778 Yorvipath method of use 75 2037-09-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11890326 Yorvipath composition of matter 17 2037-09-28
11890326 Yorvipath composition of matter 17 2037-09-28
11890326 Yorvipath composition of matter 17 2037-09-28
11918628 Yorvipath composition of matter 17 2037-09-28
11918628 Yorvipath composition of matter 17 2037-09-28
11918628 Yorvipath composition of matter 17 2037-09-28
11759504 Yorvipath formulation 55 2037-09-28
11759504 Yorvipath formulation 55 2037-09-28
11759504 Yorvipath formulation 55 2037-09-28
12403182 Yorvipath method of use 75 2042-11-12

Related